

ASPEN PHARMACARE HOLDINGS LIMITED  
(Incorporated in the Republic of South Africa) ("Aspen Holdings")  
Registration number: 1985/002935/06  
Share code: APN  
ISIN: ZAE000066692  
LEI: 635400ZYSN1IRD5QWQ94  
and its subsidiaries (collectively "Aspen" or "the Group")

## **CONFIRMATION OF RELEASE OF INTEGRATED REPORT AND FURTHER NOTICE OF ANNUAL GENERAL MEETING TO BE HELD ON 9 DECEMBER 2021**

### **1. POSTING OF AGM NOTICE AND ABBREVIATED REPORT**

Shareholders are advised that the Company's Integrated Report for the year ended 30 June 2021 has been finalised and that the notice of the annual general meeting ("AGM") to be held at its Durban offices on 9 December 2021 is in the process of being posted to shareholders, along with a set of abbreviated annual financial statements ("AFS"). The following documents are now available on the Company's website [www.aspenpharma.com](http://www.aspenpharma.com) (at the following link <https://www.aspenpharma.com/investor-information/>):

- Integrated Report for the 2021 financial year;
- Notice of AGM and proxy in respect of the AGM to be held on 9 December 2021;
- Reports of the Aspen Audit & Risk and Social & Ethics committees for the 2021 financial year;
- Full AFS for the 2021 financial year (as approved by the Company's Board on 4 October 2021 and uploaded to the Company's website on that date – shareholders are referred to the No Change Statement and Notice of Annual General Meeting as released on 4 October 2021; and
- Various other reports supplementary to the Integrated Report.

### **2. NOTICE OF AGM**

Further notice is hereby given that the 23<sup>rd</sup> annual general meeting of the shareholders of the Company will be held at Aspen Place, 9 Rydall Vale Park, Douglas Saunders Drive, La Lucia Ridge Office Park, Durban, Kwa-Zulu Natal, on Thursday, 9 December 2021 at 10:00. *Should you choose to attend the meeting in person, please ensure that you contact the Company Secretary & Group Governance Officer at [rverster@aspenpharma.com](mailto:rverster@aspenpharma.com) / 031 580 8624 by no later than 10:00 on Monday, 6 December 2021 in order to ensure compliance with COVID-19 regulations and requirements.*

The record date on which a person must be registered as a shareholder in the register of the Company for purposes of being entitled to attend and participate in, and speak and vote at, the meeting is Friday, 3 December 2021. Accordingly, the last day to trade in order to be registered in the register of members of the Company and therefore be eligible to participate in and vote at the annual general meeting is Tuesday, 30 November 2021. Shareholders are requested, but are not obliged, to submit their completed forms of proxy to the Company's transfer secretaries (JSE Investor Services) before 10:00 on Tuesday, 7 December 2021.

Shareholders who, for whatever reason, experience postal delays and who do not receive the notice of the AGM in time to submit proxy forms to the Company's share transfer secretaries (JSE Investor Services) are requested to access the notice of AGM and other documents referred to above on the Company's website [www.aspenpharma.com](http://www.aspenpharma.com). A printable version of these documents in PDF format can also be emailed to shareholders upon request to the Company Secretary – [rverster@aspenpharma.com](mailto:rverster@aspenpharma.com) or +27 31 580 8624.

**Electronic participation**

Shareholders or their proxies or representatives may participate in (but not vote at) the meeting by way of telephone / video conference call, and if they wish to do so:

- Must contact the Company Secretary & Group Governance Officer (by email at the address [rverster@aspenpharma.com](mailto:rverster@aspenpharma.com)) by no later than 10:00 on Friday 3 December 2021 in order to obtain the dial-in details / meeting link in order to participate in the meeting;
- Will be required to provide reasonably satisfactory identification; and
- Will be billed separately by their own service providers for the costs incurred in respect of their telephone / video call to participate in the meeting.

**3. BROAD-BASED BLACK ECONOMIC EMPOWERMENT CERTIFICATE**

Shareholders are hereby notified that in accordance with the JSE Listings Requirements, the Company's B-BBEE compliance report in terms of section 13G(2) of the Broad-Based Black Economic Empowerment Act 53 of 2003 read with the Broad-Based Black Economic Empowerment Act 46 of 2013, is in the process of being submitted to the BEE Commission and will be made available on the Company's website [www.aspenpharma.com](http://www.aspenpharma.com) as soon as the submission process has completed. A further announcement in this regard will be made to shareholders.

Durban

28 October 2021

**Sponsor**

**Investec Bank Limited**